Search
Subasumstat
go.drugbank.com/drugs/DB16406InvestigationalSubasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced
INCB-9471
go.drugbank.com/drugs/DB12960InvestigationalINCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.
UDP-alpha-D-glucuronic acid
go.drugbank.com/drugs/DB03041ExperimentalIt may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.
5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine
go.drugbank.com/drugs/DB08666ExperimentalThis compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This drug targets the protein methionine aminopeptidase.
Carthamus tinctorius flower bud
go.drugbank.com/drugs/DB14278ApprovedCarthamus tinctorius flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Zanthoxylum clava-herculis whole
go.drugbank.com/drugs/DB14353ApprovedZanthoxylum clava-herculis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
TN-401
go.drugbank.com/drugs/DB18140InvestigationalTN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Synonyms: A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 geneElismetrep
go.drugbank.com/drugs/DB15287InvestigationalElismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).
APD668
go.drugbank.com/drugs/DB05166ExperimentalAPD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated … blood glucose levels, and to also avoid hypoglycemia.
FINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalIt is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity … , of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule.